PROMOMED entered the TOP 3 Russian pharmaceutical companies according to Forbes

March 26, 2026, Moscow

PROMOMED entered the top three pharmaceutical manufacturers in Russia by the end of 2025. The corresponding rating was published by the business publication Forbes. It is based on an in—depth analysis of business indicators reflecting companies' contribution to the development of the domestic pharmaceutical industry.

The Forbes rating is based on data from the analytical company AlphaRM and covers the 40 largest Russian pharmaceutical manufacturers in terms of sales. The assessment was carried out according to several key criteria, among which the highest weight was given to the proportion of drugs produced in Russia at the stage of the finished dosage form. The volume of sales in 2025, revenue growth, the number of registered brands in circulation, as well as innovation activity — the number of permits for clinical trials over a ten-year period (from 2016 to 2025) - were taken into account.

During the year, PROMOMED improved its position in the rating by 4 positions, demonstrating an increase from 7th to 3rd place. In 2025, the Company grew 6 times faster than the growth rate of the entire pharmaceutical market. This dynamic was achieved due to the successful launch of a number of drugs on the market, including the first domestic tirzepatide Tirzetta® for the treatment of type 2 diabetes and obesity; an innovative version of semaglutide Velgia® Eco without preservatives; the first domestic apalutamide for the treatment of prostate cancer; as well as the first-in-class drug for lung tissue repair AMBERWIN® Pulmo and modern painkillers Wright Bufen and Migrenium® Neo. In addition, the Company launched the first subscription system for course—based medications in the history of the Russian pharmaceutical industry, allowing patients to save on treatment, and also received a registration certificate for Semaltara®, the first Russian semaglutide in tablet form that combines high efficiency with ease of use.[1]

PROMOMED considers its position in the rating as confirmation of the effectiveness of the chosen development strategy, which includes investments in its own developments, localization of complex drugs and expansion of production capabilities. The company continues to focus on strengthening its position as one of the leading domestic manufacturers capable of providing the market with high-quality and affordable medicines.

___________________________

[1] - The drugs are prescription drugs, have contraindications and should be purchased only as prescribed by a doctor. Please read the instructions before use. Do not use the drug unless it has been prescribed by a doctor. During therapy, follow the instructions for use and the recommendations of your doctor.